Predictors of human papillomavirus infection in women undergoing routine cervical cancer screening in Spain: the CLEOPATRE study by Esther Roura et al.
RESEARCH Open Access
Predictors of human papillomavirus infection in
women undergoing routine cervical cancer
screening in Spain: the CLEOPATRE study
Esther Roura1, Thomas Iftner2, José Antonio Vidart3, Susanne Krüger Kjaer4,5, F Xavier Bosch1, Nubia Muñoz6,
Santiago Palacios7, Maria San Martin Rodriguez8, Carmen Morillo8, Laurence Serradell9, Laurence Torcel-Pagnon9,
Javier Cortes10 and Xavier Castellsagué1*, for the CLEOPATRE Spain Study Group
Abstract
Background: Human papillomavirus (HPV) is a sexually transmitted infection that may lead to development of
precancerous and cancerous lesions of the cervix. The aim of the current study was to investigate socio-
demographic, lifestyle, and medical factors for potential associations with cervical HPV infection in women
undergoing cervical cancer screening in Spain.
Methods: The CLEOPATRE Spain study enrolled 3 261 women aged 18–65 years attending cervical cancer
screening across the 17 Autonomous Communities. Liquid-based cervical samples underwent cytological
examination and HPV testing. HPV positivity was determined using the Hybrid Capture II assay, and HPV
genotyping was conducted using the INNO-LiPA HPV Genotyping Extra assay. Multivariate logistic regression was
used to identify putative risk factors for HPV infection.
Results: A lifetime number of two or more sexual partners, young age (18–25 years), a history of genital warts, and
unmarried status were the strongest independent risk factors for HPV infection of any type. Living in an urban
community, country of birth other than Spain, low level of education, and current smoking status were also
independent risk factors for HPV infection. A weak inverse association between condom use and HPV infection was
observed. Unlike monogamous women, women with two or more lifetime sexual partners showed a lower risk of
infection if their current partner was circumcised (P for interaction, 0.005) and a higher risk of infection if they were
current smokers (P for interaction, 0.01).
Conclusion: This is the first large-scale, country-wide study exploring risk factors for cervical HPV infection in Spain.
The data strongly indicate that variables related to sexual behavior are the main risk factors for HPV infection. In
addition, in non-monogamous women, circumcision of the partner is associated with a reduced risk and smoking
with an increased risk of HPV infection.
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Background
Human papillomavirus (HPV) is one of the most com-
mon sexually transmitted infections worldwide. It is well
established that HPV is the necessary cause of cervical
cancer and its precancerous lesions. In addition, HPV
has been associated with a wide range of other diseases
including: genital warts; vulvar, vaginal, penile and anal
cancers; head and neck cancers; and recurrent respira-
tory papillomatosis [1,2]. Most sexually active women
will be infected with HPV during their lifetime [3].
While the majority of HPV infections are cleared within
2 years, persistent infections and the presence of risk
factors that promote persistence may lead to the devel-
opment of precancerous and cancerous lesions in a
small fraction of women. HPV genotypes are classified
as high-risk (HR) or low-risk (LR) based on their associ-
ation with cervical cancer, HPV 16 being the type most
commonly identified in this cancer [4].
Epidemiological studies conducted among women over
the past decade have shown consistently that the preva-
lence of cervical HPV infection, particularly HR HPV
types, is greatest among women below the age of 25–
30 years and lower in older women [5,6]. The increased
infection rates among young women are attributable to
higher exposure to HPV through multiple sexual part-
ners. In contrast, older women tend to have fewer new
partners and they may have developed some degree of
immunity against HPV [7]. Other potential risk factors
for cervical HPV infection include tobacco smoking [8],
nulliparity [9], use of oral contraceptives [9], and recent
new sexual partners [10]. Use of condoms may protect
against cervical HPV infection [11].
Data on cervical HPV prevalence and determinants of
HPV infection are sparse and limited in Spain. In a pre-
vious analysis of the CLEOPATRE Spain study, we
reported the prevalence and type-specific distribution of
cervical HPV infection among women aged 18–65 years
attending cervical cancer screening in Spain [12]. In the
current analysis we report on the association between
socio-demographic, lifestyle and medical factors and the
prevalence of cervical HPV infection. Only one previous
epidemiological study has been carried out in the general
female population of Spain to assess these risk factors
[13]. Thus, the current analysis represents the first large-
scale, country-wide epidemiological study exploring risk
factors for cervical HPV infection in Spain.
Methods
Study participants and procedures
The CLEOPATRE Spain study was a cross-sectional study
conducted between June 2007 and May 2008 in 77 centers
across the 17 Autonomous Communities in Spain. The
study methods have been described previously in detail
[12]. Briefly, women aged 18–65 years attending routine
cervical cancer screening were recruited, excluding virgins
and women who had a history of HPV-related cervical dis-
ease or HPV vaccination. All study participants provided
written informed consent. Ethical clearance was obtained
from the ethical committee of the Hospital Clínico San
Carlos (Madrid, Spain).
Demographic and socio-economic data, information
about sexual behavior, smoking habits, and medical his-
tory were collected after enrollment and recorded on a
case report form. A liquid-based cytology (LBC) sample
was collected from each participant. The LBC samples
were sent to central laboratories for cytological diagnosis
(Biomnis, R. Dachez, Paris, France), HPV detection
(Biomnis, C. Ronsin, Ivry, France), and genotyping (In-
stitute of Medical Virology, T. Iftner, University Hospital,
Tübingen, Germany). HPV positivity was defined using
the HPV DNA test, Hybrid Capture II (HC2; Digene
Corporation, Gaithersburg, MD, USA). The HC2 assay
uses two RNA probes, one to detect 13 HR types (16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) and an-
other one to detect 5 LR types (6, 11, 42, 43, and 44) in
cervical samples [14]. Samples were considered to be
HPV-positive if either of the two probes (low- and/or
high-risk probes) were positive at a relative light unit co-
efficient (RLU/Co) of ≥1.0, which corresponds to the
HPV DNA threshold of 1.0 pg/mL recommended by the
United States Food and Drug Administration (US FDA).
HPV genotyping was determined in all study samples
using the INNO-LiPA HPV Genotyping Extra assay
(Innogenetics, Gent, Belgium). Only results of HPV
genotyping for the HPV-HC2-positive women are
shown. The INNO-LiPA test allows identification of 13
established HR HPV types (16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, and 66), 5 known or putative HR types
(26, 53, 68, 73, and 82), 7 LR HPV types (6, 11, 40, 43,
44, 54, and 70), additional non-differentiated HPV types,
and types with undefined risk (74 and 69/71). Auto-
mated results were confirmed with blinded manual read-
ings undertaken by experienced laboratory personnel.
Risk factor analysis
The evaluation of potential risk factors included age, type
of community (rural, suburban or urban based on popula-
tion size of municipality), country of birth, marital status,
level of education, professional status, smoking status (in-
cluding duration and intensity), pregnancies, contracep-
tive methods, lifetime number of sexual partners, age at
first sexual intercourse, time since first sexual intercourse,
history of cervical lesions, history of sexually transmitted
infections (STIs), current partner’s history of STIs in the
last 12 months, current partner’s circumcision status, and
immune status.
The association between cervical HPV infection and
potential risk factors was tested by multivariate analysis,
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which involved construction of an adjusted logistic re-
gression model using stepwise regression with forward
selection. Beginning with a basic model adjusted for age
and Autonomous Community, the variables for the po-
tential risk factors were added one at a time into the
model to evaluate their association with cervical HPV
infection, and those that showed a statistically significant
association (P-value <0.10) were retained in the final
model as adjusting variables.
Adjusted models were also constructed to evaluate the
association between potential risk factors and HR HPV,
LR HPV, HPV 16, and single and multiple HPV infec-
tions. Analyses were conducted to explore multiplicative
interactions between lifetime number of sexual partners
and other potential risk factors for cervical HPV infec-
tion. In addition, an adjusted model was constructed to
assess risk factors for HPV positivity among young
women aged 18–25 years.
Analyses were performed using the R programing




A total of 7 252 women were initially registered in the
recruitment logs at the participating sites. Of those, 4
206 were eligible and 3 261 were finally enrolled in the
study. The participation rate was 77.5% (3 261/4 206).
Reasons for non-participation among eligible women
were: refusal (13.2%), and other reasons such as logistic
problems or menstruation (9.3%). The characteristics of
study participants have been described previously [12].
In brief, 91.3% of the women were born in Spain, 77.2%
lived in an urban area (≥10 000 inhabitants), 39.7% were
single, 33.0% had a university/college education, 25.5%
were students, 35.6% were current smokers, and 19.5%
reported having had four or more lifetime sexual part-
ners. There was a planned oversampling of young
women aged ≤25 years (49.6%) compared with the
proportion of this age group in the overall female popu-
lation of Spain (18.0%).
Prevalence of HPV
HC2 results were available for 3 155 (96.7%) women
[12]. A total of 608 (19.3%) women were HPV-positive
based on the HC2 assay, 527 of whom (86.7%) were
infected with one or more HR types (with or without
concomitant LR HPV infection). LiPA results were avail-
able for 606 HC2-positive samples (497 LiPA positive
and 109 LiPA negative). Single and multiple HPV infec-
tions were detected in 49.2% (298/606) and 32.8% (199/
606) of these samples, respectively.
Risk factor analysis
Risk factors for any HPV infection
In the basic model adjusted for age and Autonomous
Community, the following characteristics were positively
and statistically significantly associated with cervical
HPV infection: young age; living in an urban commu-
nity; country of birth other than Spain; unmarried status;
current smoker; more than one lifetime sexual partner;
young age at first sexual intercourse (with a statistically
significant trend); more years elapsed since first inter-
course (with a statistically significant trend); and a his-
tory of cervical lesions, genital warts or other STIs
(Table 1). There was also a weak and statistically border-
line inverse association between systematic use of con-
doms in the last 12 months, meaning use of condom in
90-100% of all sexual relationships that occurred in the
last year, and cervical HPV infection. No associations
were identified between cervical HPV infection and
number of pregnancies, use of oral contraceptives, ever
use of condoms or a current sexual partner who was cir-
cumcised or with STIs in the last 12 months. Other vari-
ables, including type of medical practice and setting,
professional status, duration and intensity of smoking,
use of an intrauterine device, and immune status, were
also assessed but no associations with HPV infection
were observed (data not shown).
In the final adjusted model, variables that remained
statistically significant were: age 18–25 years; living in an
urban community; country of birth other than Spain;
unmarried status; lower level of educational attainment
(with a statistically significant trend); current smoker;
more than one lifetime sexual partner; and a history of
genital warts (Table 2). A high lifetime number of sexual
partners, a history of genital warts, and unmarried status
were the risk factors most strongly associated with cer-
vical HPV infection. Notably, women who had four or
more sexual partners had a 4-fold higher risk of being
HPV-positive than women who had only one sexual
partner.
It is interesting to note that the pattern of association
with age at first intercourse in the adjusted model was
opposite to that found in the basic model. While in the
crude analysis young age at first intercourse was asso-
ciated with increased HPV prevalence, in the fully
adjusted model this effect was reversed and young age at
first intercourse was associated with reduced HPV preva-
lence (P for trend = 0.003) (Table 2). To explore these
associations further, we performed stratified analyses by
levels of lifetime number of sexual partners and levels of
age at first sexual intercourse (Figure 1). As shown in
Figure 1a, HPV prevalence was not associated with age at
first intercourse within each category of number of sex-
ual partners. In contrast, Figure 1b shows that HPV
prevalence was strongly associated with lifetime number
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Table 1 Prevalence of cervical human papillomavirus















18 80/308 26.0 4.8 3.1–7.5
19 101/339 29.8 5.7 3.7–8.8
20–21 131/452 29.0 5.5 3.6–8.3
22–25 137/471 29.1 5.5 3.6–8.2
26–35 54/319 16.9 2.7 1.7–4.3
36–45 31/326 9.5 1.4 0.8–2.3
46–55 42/486 8.6 1.2 0.8–2.0
56–65 32/454 7.0 1 reference
P-value for trend <0.001
Residential area
Rural 48/329 14.6 1 reference
Suburban 71/393 18.1 1.3 0.8–1.9
Urban 488/2428 20.1 1.6 1.1–2.2
Unknown 5 - - -
P-value for trend 0.005
Country of birth
Spain 525/2886 18.2 1 reference
Other countries 83/269 30.9 1.7 1.3–2.3
Marital status
Single 361/1259 28.7 3.4 2.4–4.9
Cohabiting 137/549 25.0 2.9 2.0–4.3
Married 71/1158 6.1 1 reference
Divorced/Separated 28/127 22.0 4.4 2.7–7.1
Widowed 11/62 17.7 3.9 1.9–8.0
Level of educational
attainment
No formal education 27/178 15.2 1 reference
Primary completed 92/648 14.2 0.9 0.5–1.4
Secondary completed 290/1286 22.6 1.0 0.6–1.5
University or higher 199/1040 19.1 0.7 0.5–1.2
Unknown 3 - - -
P-value for trend 0.07
Tobacco smoking
status
Never smoked 227/1599 14.2 1 reference
Ex-smoker 57/439 13.0 1.2 0.8–1.6
Current smoker 324/1116 29.0 2.3 1.8–2.8
Unknown 1 - - -
Table 1 Prevalence of cervical human papillomavirus
infection and crude associations between infection and
selected subjects’ characteristics (Continued)
P-value for trend <0.001
Number of
pregnancies
0 330/1340 24.6 1 reference
1 93/417 22.3 1.3 1.0–1.8
2 62/587 10.6 1.0 0.7–1.4
≥3 43/511 8.4 0.8 0.5–1.3






Never used 240/1299 18.5 1 reference
Ex-user 192/1141 16.8 1.2 1.0–1.5
Current user 176/712 24.7 1.0 0.8–1.2
Unknown 3 - - -
Ever use of condoms
Never used 85/650 13.1 1 reference
Ex-user 162/1003 16.2 1.0 0.7–1.4
Current user 361/1502 24.0 1.1 0.8–1.5
Systematic condom
use in last 12 months*
No 359/1947 18.4 1 reference
Yes 226/1031 21.9 0.8 0.6–1.0
Unknown 12 - - -
Lifetime number
of sexual partners
1 139/1560 8.9 1 reference
2 103/577 17.9 1.8 1.4–2.4
3 122/397 30.7 3.9 2.9–5.3
≥4 241/609 39.6 5.8 4.5–7.5
Unknown 12 - - -
P-value for trend <0.001
Age at first sexual
intercourse (years)
≤14 41/125 32.8 2.1 1.0–4.5
15–16 192/685 28.0 1.6 0.8–3.1
17–18 235/1097 21.4 1.3 0.7–2.5
19–20 69/492 14.0 1.2 0.6–2.3
21–25 58/595 9.7 1.1 0.6–2.2
≥26 11/145 7.6 1 reference
Unknown 16 - - -
P-value for trend 0.006
Current partner had
STIs in last 12 months
No 538/2888 18.6 1 reference
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of sexual partners within each category of age at first
intercourse (P< 0.001 for each age stratum). These
stratified analyses show that HPV prevalence is more
strongly associated with lifetime number of sexual part-
ners than with age at first sexual intercourse. A similar
effect was obtained when evaluating time since first sex-
ual intercourse instead of age at first intercourse.
Interaction between lifetime number of sexual partners,
male circumcision, and smoking status
Interaction analyses showed that having a current partner
who was circumcised had a significant protective effect
against cervical HPV infection in women reporting two or
more lifetime sexual partners but not in monogamous
women (P for interaction = 0.005) (Table 3). A synergistic
interaction with cervical HPV infection was also observed
between smoking and having two or more lifetime sexual
partners. Thus, the risk of infection almost doubled in
women reporting two or more lifetime sexual partners if
they were current smokers, whereas in monogamous
women current smokers showed little increase in risk
compared with non-smokers (P for interaction = 0.01).
Table 1 Prevalence of cervical human papillomavirus
infection and crude associations between infection and
selected subjects’ characteristics (Continued)
Yes 9/38 23.7 1.1 0.5–2.4
Unknown 229 - - -
Current partner
circumcised
No 432/2366 18.3 1 reference
Yes 60/369 16.3 0.9 0.6–1.2
Unknown 420 - - -
Previous cervical
lesions
No 559/2952 18.9 1 reference
Yes 36/178 20.2 1.7 1.1–2.5
Unknown 25 - - -
History of genital
warts
No 555/3061 18.1 1 reference
Yes 50/87 57.5 4.8 3.1–7.6
Unknown 7 - - -
History of other STIs
No 579/3054 19.0 1 reference
Yes 23/87 26.4 1.7 1.0–2.8
Unknown 14 - - -
HPV, human papillomavirus; POR, prevalence odds ratio; CI, confidence
interval; STI, sexually transmitted infection.
1Basic model: adjusted for age and Autonomous Community.
*Among women with a sexual partner in the last 12 months.
Bold font indicates a significant effect (P< 0.05).
Table 2 Multivariate analyses of the association between








18 308 1.7 1.1–3.1
19 339 2.2 1.4–3.7
20–21 452 2.1 1.3–3.4
22–25 471 1.9 1.2–3.2
26–35 319 1.1 0.7–1.9
26–45 326 0.7 0.4–1.2
46–55 486 0.8 0.5–1.3
56–65 454 1 reference
P-value for trend <0.001
Residential area
Rural 329 1 reference
Suburban 393 1.3 0.8–2.1
Urban 2428 1.5 1.0–2.2
Unknown 5 - -
P-value for trend 0.03
Country of birth
Spain 2886 1 reference
Other countries 269 1.7 1.3–2.4
Marital status
Married 1158 1 reference
Single 1259 2.1 1.4–3.1
Cohabiting 549 1.8 1.2–2.6
Divorced/Separated 127 2.3 1.4–3.4
Widowed 62 3.7 1.7–7.7
Level of education
attainment
No formal education 178 1 reference
Primary completed 648 0.9 0.5–1.5
Secondary completed 1286 0.9 0.5–1.4
University or higher 1040 0.7 0.4–1.1
Unknown 3 - -
P-value for trend 0.02
Tobacco smoking status
Never smoked 1599 1 reference
Ex-smoker 439 1.0 0.7–1.3
Current smoker 1116 1.6 1.3–1.9
Unknown 1 - -
P-value for trend <0.001
Ever use of condoms
Never used 650 1 reference
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No other statistically significant interactions with lifetime
number of sexual partners were found.
Risk factors for HPV infection in young women
We examined the potential risk factors associated with
HPV infection among young women aged ≤25 years. In
the adjusted model, the lifetime number of sexual part-
ners, a history of genital warts, a country of birth other
than Spain, and current smoking status were identified
as the most important risk factors for cervical HPV in-
fection (data not shown). Young age at first intercourse
was associated with decreased HPV prevalence (P for
trend = 0.006). Accordingly, increasing time since first
sexual intercourse was also inversely associated with
HPV infection (P for trend = 0.06).
Risk factors for HR versus LR HPV infections and for HPV 16
infections
We explored whether the determinants for HR HPV in-
fection differed from those for LR infection by carrying
out a stratified analysis (Table 4). The risk factors for
HR infections (Table 4) were the same as those for any
HPV infection (Table 2). In contrast, the determinants
for LR HPV infection were: history of genital warts, in-
creasing lifetime number of sexual partners, being single,
and (inversely but weakly) ever use of condoms (Table 4).
We also compared the risk factors for HR versus LR
HPV infections by modeling infected women only. The
following factors were positively associated with HR as
compared to LR infection: birth in countries other than
Spain, ever use of condoms, and a history of previous
cervical lesions (data not shown).
Determinants associated with HPV 16 infection, com-
pared with HPV-negative women, were also evaluated.
Women of young age, smokers, and women with more
than two lifetime sexual partners had an increased risk
of HPV 16 infection (data not shown).
Risk factors for single versus multiple HPV infections
In a stratified adjusted model, the same variables as those
identified in the adjusted model for any HPV infection
(Table 2) were independently associated with single or
multiple HPV infections (Table 5), except for residential
area. Furthermore, ever use of condoms had a borderline
protective effect against single HPV infection but not
against multiple infection. Regression models comparing
potential risk factors for multiple versus single HPV
infections showed that women with more than two life-
time sexual partners were more likely to have multiple
than single HPV infections (data not shown).
Discussion
This is the first large-scale, country-wide study in Spain
to evaluate potential risk factors for cervical HPV infec-
tion. In addition to young age, a lifetime number of two
or more sexual partners, a history of genital warts, and
being unmarried were the strongest risk factors for cer-
vical HPV infection among women aged 18–65 years
attending routine cervical cancer screening across Spain.
Living in an urban community, country of birth other
than Spain, low level of education, and current smoking
were also identified as independent risk factors for
Table 2 Multivariate analyses of the association between
cervical human papillomavirus infection and selected
subjects’ characteristics (Continued)
Ex or current user 2505 0.9 0.6–1.1
Systematic condom
use in last 12 months*
No 1947 1 reference
Yes 1031 0.8 0.6–1.0
Unknown 12 - -
Lifetime number of
sexual partners
1 1560 1 reference
2 577 1.5 1.1–2.1
3 397 3.3 2.5–4.5
≥4 609 4.1 3.1–5.4
Unknown 12 - -
P-value for trend <0.001
Age at first sexual
intercourse (years)
≤14 125 0.5 0.2–1.2
15–16 685 0.6 0.3–1.2
17–18 1097 0.7 0.3–1.4
19–20 492 0.8 0.4–1.6
21–25 595 1.0 0.5–2.1
≥26 145 1 reference
Unknown 16 - -
P-value for trend 0.003
Current partner
circumcised
No 2366 1 reference
Yes 369 0.8 0.6–1.1
Unknown 420 - -
History of genital warts
No 3061 1 reference
Yes 87 3.2 2.0–5.2
Unknown 7 - -
POR, prevalence odds ratio; CI, confidence interval.
1Adjusted model: adjusted for age, Autonomous Community, country of birth,
marital status, level of education, smoking habits, lifetime number of sexual
partners, and history of genital warts.
*Among women with a sexual partner in the last 12 months.
Bold font indicates a significant effect (P< 0.05).
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cervical HPV infection. Condom use provided a border-
line protective effect against HPV infection.
Our results agree with those of a previous epidemio-
logical study in the general female population of Spain
(N= 973) conducted in 2003 by de Sanjose et al., which
found the following independent risk factors of HPV in-
fection: overseas birth, divorce, more than one sexual
partner, and smoking marijuana or related products. Use
of condoms with a regular partner was found to be pro-
tective against HPV, but with a borderline effect [13].
As in other studies [7,10,11,13], an increased lifetime
number of sexual partners was the most consistent risk
factor for cervical HPV infection identified in our study.
In contrast, age at first sexual intercourse was not identi-
fied as an independent risk factor in the multivariate
analysis, in accordance with some previous studies
[7,10,13]. In our study, young age at first intercourse
increased the risk of HPV infection in the unadjusted
model but in the adjusted one the effect was reversed.
The inclusion of number of sexual partners in the
adjusted model explained this change, indicating reverse
co-linearity between the two variables. Our further strati-
fied analyses, as shown in Figure 1, strongly suggested
that the key determinant of cervical HPV infection is the
number of sexual partners the woman had had and not
the age at first sexual intercourse. These findings are in
agreement with other studies suggesting that age at sex-
ual debut is a likely predictor of lifetime number of sex-
ual partners and not a factor independently associated
with cervical HPV infection [15,16]. A similar effect was
observed when time since first sexual intercourse was
assessed rather than age at first sexual intercourse.
Country of birth other than Spain was identified as an
independent risk factor for cervical HPV infection, a
finding that was reported in a previous, smaller study
conducted in Spain [13]. In our study, most women born
outside Spain were immigrants from Latin America. The
HPV prevalence in these countries is higher than that in
Spain [17,18]. The increased prevalence of HPV among
immigrant women compared with women born in Spain
may be related to well-known differences in sexual be-
havior in both men and women.
In agreement with the pooled analysis of the Inter-
national Agency for Research on Cancer (IARC) on
smoking and HPV prevalence [8], we identified current
smoking status as an independent risk factor for cervical
HPV infection. A large population-based study con-
ducted in women from Costa Rica found a positive asso-
ciation between smoking status and HPV 16, an
association that was also found to be statistically signifi-
cant in our study [10]. Intensity of smoking was
Figure 1 Prevalence odds ratios for human papillomavirus*. (a) The association between cervical HPV infection and age at first sexual
intercourse stratified by lifetime number of sexual partners. Reference group: ≥21 years of age at first sexual intercourse. (b) The association
between cervical HPV infection and lifetime number of sexual partners stratified by age at first sexual intercourse. Reference group: 1 sexual
partner. P< 0.001 for association for each age stratum. *Model adjusted for age, Autonomous Community, country of birth, marital status, level of
education, smoking habits, and history of genital warts.
Table 3 Association between male circumcision, smoking,













No (reference) 1.0 1.0




Never/ex-smoker (reference) 1.0 1.0
Current smoker 1.1 (0.7–1.7) 2.0 (1.6–2.5)
POR, prevalence odds ratio; CI, confidence interval.
*Log-Likelihood test.
Model adjusted for age, Autonomous Community, country of birth, marital
status, level of education, smoking habits, lifetime number of sexual partners,
and history of genital warts.
Bold font indicates a significant effect (P<0.05).
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Table 4 Multivariate analyses of the association between
high- and low-risk human papillomavirus infections and
selected subjects’ characteristics
Any HR HPV vs. negative
(n=3074)







POR 95% CI POR 95% CI
Age group
(years)
18 302 2.3 1.3–4.1 234 0.7 0.2–2.3
19 327 2.7 1.5–4.7 250 1.4 0.5–4.0
20–21 440 2.6 1.5–4.5 333 0.9 0.3–2.6
22–25 449 2.2 1.3–3.8 356 1.6 0.6–4.2
26–35 312 1.3 0.7–2.3 272 0.7 0.2–2.3
36–45 325 0.9 0.5–1.7 296 0.1 0.0–0.8
46–55 474 0.8 0.4–1.4 456 1.1 0.4–2.8





Rural 324 1 reference 286 1 reference
Suburban 383 1.3 0.8–2.1 332 1.5 0.5–4.7
Urban 2362 1.5 1.0–2.2 2006 1.5 0.6–4.1





Spain 2811 1 reference 2436 1 reference
Other
countries
263 2.0 1.4–2.8 192 0.6 0.2–1.6
Marital status
Married 1143 1 reference 1102 1 reference
Single 1214 2.1 1.4–3.2 943 2.8 1.1–7.1
Cohabiting 533 1.7 1.1–2.7 428 2.3 0.9–5.9
Divorced/
Separated
125 2.7 1.5–4.7 101 0.8 0.2–3.6






177 1 reference 152 1 reference
Primary
completed
640 0.9 0.5–1.5 564 2.2 0.3–18.5
Secondary
completed
1241 0.7 0.4–1.2 1041 5.6 0.7–42.4
University
or higher
1013 0.6 0.3–1.0 868 3.8 0.5–30.1




Table 4 Multivariate analyses of the association between
high- and low-risk human papillomavirus infections and






1566 1 reference 1405 1 reference
Ex-smoker 426 0.9 0.6–1.3 395 1.4 0.7–2.8
Current
smoker
1081 1.6 1.3–2.1 827 1.2 0.7–2.0






Never used 630 1 reference 585 1 reference
Ex or current
user





No 1902 1 reference 1633 1 reference
Yes 1001 0.8 0.6–1.0 835 1.0 0.6–1.7





1 1534 1 reference 1447 1 reference
2 564 1.6 1.2–2.2 487 1.2 0.6–2.4
3 383 3.5 2.6–4.9 289 2.6 1.3–5.2
≥4 581 4.4 3.3–5.9 396 3.0 1.6–5.6








≤14 121 0.7 0.3–1.8 88 0.2 0.0–1.2
15–16 671 0.8 0.3–1.9 507 0.2 0.1–0.8
17–18 1061 0.9 0.4–2.0 898 0.5 0.1–1.6
19–20 481 1.0 0.4–2.5 434 0.5 0.1–1.8
21–25 584 1.3 0.6–3.2 548 0.6 0.2–1.9
≥26 141 1 reference 138 1 reference
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identified as another predictor of HPV infection in the
IARC analysis, but these data were not statistically sig-
nificant in our adjusted model. An association between
smoking and cervical HPV infection is difficult to assess
because of the strong confounding effect of sexual be-
havior. To address this we performed further logistic re-
gression analyses to formally test for the interaction
between smoking and number of sexual partners, and
found a statistically significant interaction between the
two risk factors (Table 3). Smoking was associated with
a two-fold increased prevalence of cervical HPV in
women with multiple sexual partners but not among
monogamous women. In contrast, in the IARC study a
significant relationship of smoking intensity was seen
only among women who reported one sexual partner,
but not among women reporting more partners. A pos-
sible explanation for this interaction is that among
women with a high exposure to HPV (those with mul-
tiple partners) the risk of infection is much increased if
they are concomitantly exposed to smoking. Conversely,
smoking in the absence of high exposure to HPV is not
as relevant in determining the risk of HPV infection.
Some studies have documented that in the presence of
HPV, tobacco products may reduce local immunological
responses, which might facilitate HPV acquisition, re-
duce HPV clearance, or increase HPV persistence, thus
increasing the overall HPV prevalence [19,20].
Condom use was found to be inversely but weakly
associated with cervical HPV infection. The protective
effect of condom use against HPV infection is controver-
sial in the literature. Whereas some previous studies
have reported a weak association with HPV infection
[10,11,13], others have not [7]. Taking into account the
weak magnitude of the associations found overall and in
the subgroup analyses performed in our study, the
beneficial effect of condom use on HPV prevalence is
probably small.
Although male circumcision was not identified as a
predictor of cervical HPV infection in our study, inter-
action analyses showed a protective effect among women
at increased risk of HPV infection (i.e. women who had
more sexual partners). Previous studies have shown that
circumcised men are less likely to have penile HPV in-
fection than uncircumcised men and that male circumci-
sion infers a protective effect in female sexual partners
for cervical HPV infections as well as for cervical cancer
[21,22].
A strength of this study is that the age-stratified sam-
pling strategy used within each of the Autonomous
Communities of Spain (except Ceuta and Melilla) pro-
vided a good demographic representation of the age-
specific female population attending cervical cancer
screening across the country. However, a potential limi-
tation is that women were selected from opportunistic
cervical cancer screening programs, which may have
resulted in the preferential recruitment of health-
conscious or healthier women. This potential over-
representation of “healthy” women could underestimate
the true prevalence of risk factors related to cervical
HPV infection, such as tobacco smoking, high number
of sexual partners or having never used a condom. The
potential effect of this would be an underestimation of
the true effects related to these risk factors. In order to
assess potential selection bias, the distribution of key
socio-demographic and lifestyle characteristics of women
included in the CLEOPATRE study was compared with
that of the general female population of Spain using
public data such as marital status, parity, use of contra-
ceptive methods, and number of sexual partners among
others. We ascertained that the study population was in-
deed representative of the general female population in
Spain (data not shown). As with any other cross-
sectional design, there is a risk of reporting bias, particu-
larly in relation to variables that address aspects of sex-
ual behavior, such as “age at first sexual intercourse,”
“lifetime number of sexual partners,” and “partner’s cir-
cumcision status.” Other studies have noted also the
possibility of this non-differential misclassification
related to sexual behavior [7]. It is well known that non-
differential misclassification cannot inflate true effects;
instead, it would shift the observed association towards
the null value.
Another limitation of our study is that only 80% of the
HC2-positive samples were positive by LiPA, a much
more sensitive assay than HC2. This apparently low per-
formance of the LiPA assay may be explained by the in-
herent differences between the two assays. Although the
HC2 assay is designed to detect 18 HPV types (including
the low-risk types), several studies have noted that the
Table 4 Multivariate analyses of the association between
high- and low-risk human papillomavirus infections and
selected subjects’ characteristics (Continued)
No 2311 1 reference 1989 1 reference
Yes 359 0.7 0.5–1.0 319 1.2 0.6–2.4
Unknown 404 - - 320 - -
History of
genital warts
No 2991 1 reference 2576 1 reference
Yes 78 2.9 1.7–4.9 46 6.6 2.8–15.4
Unknown 5 - - 6 - -
HPV, human papillomavirus; HR, high-risk; LR, low-risk; POR, prevalence odds
ratio; CI, confidence interval.
1Adjusted model: adjusted for age, Autonomous Community, country of birth,
marital status, level of education, smoking habits, lifetime number of sexual
partners, and history of genital warts.
*Among women with a sexual partner in the last 12 months
Bold font indicates a significant effect (P< 0.05).
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HC2 HR probe mix may cross-react with other HPV
types that are not represented in the mix [23-25]. Data
on the cross-reactivity of the low-risk probe are not
available, but it can be assumed that cross-reactivity also
takes place with that probe. In contrast, in the LiPA test
(which is designed to detect 27 HPV genotypes by
Table 5 Multivariate analyses of the association between













POR 95% CI POR 95% CI
Age group (years)
18 268 3.1 1.4–6.8 257 3.7 1.2–11.8
19 287 3.5 1.6–7.5 273 4.1 1.3–12.9
20–21 382 3.1 1.5–6.5 369 4.0 1.3–12.5
22–25 401 3.1 1.5–6.4 387 3.8 1.2–11.7
26–35 301 2.4 1.1–4.9 279 1.5 0.4–4.9
36–45 309 0.9 0.4–2.1 304 1.4 0.4–5.0
46–55 464 1.1 0.5–2.5 451 0.97 0.3–3.5
56–65 433 1 reference 426 1 reference
P-value for trend <0.001 0.001
Residential area
Rural 305 1 reference 301 1 reference
Suburban 359 1.3 0.7–2.4 344 0.9 0.4–2.0
Urban 2176 1.4 0.9–2.4 2097 1.0 0.6–1.9
Unknown 5 - - 4 - -
P-value for trend 0.2 0.8
Country of birth
Spain 2616 1 reference 2528 1 reference
Other countries 229 2.0 1.3–3.0 218 2.2 1.3–3.5
Marital status
Married 1120 1 reference 1097 1 reference
Single 1073 2.4 1.5–4.1 1034 3.2 1.4–7.2
Cohabiting 483 2.1 1.3–3.6 452 2.0 0.9–4.7
Divorced/
Separated
114 2.6 1.3–5.2 110 5.4 2.1–14.2
Widowed 55 3.5 1.1–11.0 53 7.0 1.3–37.9
Level of education attainment
No formal
education
160 1 reference 162 1 reference
Primary
completed
600 1.3 0.6–3.0 584 0.7 0.3–1.5
Secondary
completed
1139 1.3 0.6–2.8 1095 0.6 0.3–1.4
University or
higher
943 1.1 0.5–2.3 902 0.5 0.2–1.0
Unknown 3 - - 3 - -
P-value for trend 0.4 0.03
Tobacco smoking status
Never smoked 1478 1 reference 1438 1 reference
Ex-smoker 412 1.1 0.7–1.7 398 1.0 0.5–1.8
Current smoker 954 1.7 1.3–2.3 909 1.6 1.1–2.4
Table 5 Multivariate analyses of the association between
single and multiple human papillomavirus infections and
selected subjects’ characteristics (Continued)
Unknown 1 - - 1 - -
P-value for trend <0.001 0.005
Ever use of condoms
Never used 612 1 reference 582 1 reference
Ex or
current user
2233 0.7 0.4–1.0 2164 1.1 0.6–1.9
Systematic condom use in last 12 months*
No 1761 1 reference 1707 1 reference
Yes 921 0.8 0.6–1.1 880 0.7 0.5–1.0
Unknown 12 - - 11 - -
Lifetime number of sexual partners
1 1487 1 reference 1447 1 reference
2 528 1.6 1.1–2.4 504 2.3 1.3–3.9
3 337 3.4 2.3–5.0 319 6.0 3.5–10.2
≥4 482 3.7 2.6–5.4 466 8.1 5.0–13.3
Unknown 11 - - 10 - -
p-value for trend <0.001 <0.001
Age at first sexual intercourse (years)
≤14 104 0.7 0.2–2.3 100 0.4 0.1–2.4
15–16 589 0.8 0.3–2.5 567 0.6 0.1–2.8
17–18 973 0.9 0.3–2.6 941 0.7 0.1–3.3
19–20 459 1.1 0.3–3.2 440 0.8 0.2–3.7
21–25 567 1.4 0.5–4.2 548 1.0 0.2–4.8
≥26 138 1 reference 136 1 reference
Unknown 15 - - 14 - -
P-value for trend 0.03 0.07
Current partner circumcised
No 2138 1 reference 2079 1 reference
Yes 343 0.9 0.6–1.4 327 0.7 0.4–1.3
Unknown 364 - - 340 - -
History of genital warts
No 2780 1 reference 2684 1 reference
Yes 59 2.8 1.5–5.1 58 4.4 2.3–8.8
Unknown 6 - - 4 - -
POR, prevalence odds ratio; CI, confidence interval.
1Adjusted model: adjusted for age, Autonomous Community, country of birth,
marital status, level of education, smoking habits, lifetime number of sexual
partners, and history of genital warts.
*Among women with a sexual partner in the last 12 months.
Bold font indicates a significant effect (P< 0.05).
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identification of highly specific HPV DNA sequences),
cross-reactivity with other HPV types has not been
observed. It is thus conceivable that HPV types detected
by HC2 through cross-hybridization are not detectable
with the LiPA assay. The HR probe and the LR probe,
with an unknown extent of cross-reactivity, were both
used in the present study, and this may explain the
observed relatively low sensitivity of the LiPA assay.
When comparing the two methods, a Kappa value of
0.67 (95% CI, 0.64–0.70) was found, which could be
interpreted as being acceptable.
Conclusion
This analysis of the CLEOPATRE Spain study has identi-
fied several socio-demographic, lifestyle, and medical
factors associated with cervical HPV infection. Cervical
HPV is a highly prevalent sexually transmitted infection
in women in Spain, particularly among those under
30 years of age in whom the prevalence approaches 30%.
In addition to young age, increasing number of lifetime
sexual partners and a history of genital warts were iden-
tified as key risk factors for cervical HPV infection, par-
ticularly for HR HPV, reinforcing knowledge that
cervical HPV infection is acquired early in a woman’s
sexual life. Living in an urban community, country of
birth other than Spain, low level of education, and
current smoking were also identified as independent risk
factors for HPV infection. A weak inverse association
between condom use and HPV infection was also
observed. In non-monogamous women, circumcision of
the partner was associated with a reduced risk of HPV
infection and smoking with an increased risk of HPV in-
fection. Our results emphasize the importance of HPV
vaccination programs for young women before they ac-
quire sexual partners to prevent HR and LR HPV infec-
tions. Surveys of cervical HPV prevalence and its related
risk factors increase our understanding of the natural
history of this infection and establish the basis for future
assessments of the impact of HPV immunization pro-
grams and the dynamics of risk factors for HPV infec-
tion in the population of Spain.
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